Answers are grounded in this paper and cite their sources.
Mesenchymal stem cell (MSC) has just been as the first “off-the-shelf” stem cell drug with an anticipation of more following completion of numerous rigorous trials. Despite this progress, the rationale for MSC efficacy remains tenuous and is increasingly on a secretion rather than differentiation. Recent studies identifying exosome as the agent mediating MSC therapeutic efficacy could reduce a cell-based drug to a safer biologicbased. Here we review the development of exosome as a potential first-in-class therapeutic, and unique challenges in the manufacture and regulatory of this new class of therapeutics.
No takes yet. Share an insight, caveat, or question.
Ronne Wee Yeh Yeo (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: